These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 1615556)
1. [Analysis of the genetic predisposition to cancer in families of patients with multiple primary malignant neoplasms]. Gar'kavtseva RF; Kazubskaia TP; Sel'chuk VIu Tsitol Genet; 1992; 26(2):32-6. PubMed ID: 1615556 [TBL] [Abstract][Full Text] [Related]
2. [Genetic analysis and elaboration of principles for predicting malignant tumors in families of patients with stomach cancer and primary multiple malignant neoplasms]. Kazubskaia TP; Gar'kavtseva RF Genetika; 1995 Mar; 31(3):410-4. PubMed ID: 7607430 [TBL] [Abstract][Full Text] [Related]
3. Primary breast and colon cancer associated with endometrial or ovarian cancer. Auranen SA; Grénman SK; Mäkinen JI; Salmi TA Ann Chir Gynaecol Suppl; 1994; 208():5-9. PubMed ID: 8092772 [TBL] [Abstract][Full Text] [Related]
4. [Current status and perspectives for genetic consultation and prophylactic medical examination of risk groups with malignant neoplasms of the female reproductive system and breast]. Akulenko LV; Gar'kavtseva RF; Zhordania KI; Samgina AA Tsitol Genet; 1992; 26(1):38-42. PubMed ID: 1621284 [TBL] [Abstract][Full Text] [Related]
6. [Hereditary predisposition for cancer of the breast and the ovary]. Lalle P; Stoppa-Lyonnet D; Mazoyer S; Rio P; Girodet C; Hardouin A; Narod SA; Sobol H; Bignon YJ Bull Cancer; 1993 Oct; 80(10):857-65. PubMed ID: 8204923 [TBL] [Abstract][Full Text] [Related]
7. [Genetic predisposition and ovarian cancer]. Coupier I; Gauthier-Villars M; This P; Stoppa-Lyonnet D Rev Prat; 2004 Oct; 54(16):1757-62. PubMed ID: 15630879 [TBL] [Abstract][Full Text] [Related]
8. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101 [TBL] [Abstract][Full Text] [Related]
9. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE; Gallinger S; McCready DR; Rosen B; Engel J; Malkin D CMAJ; 1996 Jan; 154(2):149-55. PubMed ID: 8548703 [TBL] [Abstract][Full Text] [Related]
10. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? Soliman PT; Broaddus RR; Schmeler KM; Daniels MS; Gonzalez D; Slomovitz BM; Gershenson DM; Lu KH J Clin Oncol; 2005 Dec; 23(36):9344-50. PubMed ID: 16361634 [TBL] [Abstract][Full Text] [Related]
11. A molecular genetic and statistical approach for the diagnosis of dual-site cancers. Brinkmann D; Ryan A; Ayhan A; McCluggage WG; Feakins R; Santibanez-Koref MF; Mein CA; Gayther SA; Jacobs IJ J Natl Cancer Inst; 2004 Oct; 96(19):1441-6. PubMed ID: 15467033 [TBL] [Abstract][Full Text] [Related]
12. [Experiences from a clinic for patients with hereditary cancer. Diagnosis of genetic carriers may prevent cancer]. Lindblom A; Iselius L Lakartidningen; 1995 May; 92(18):1915-8. PubMed ID: 7746044 [No Abstract] [Full Text] [Related]
13. Relationship of epithelial ovarian cancer to other malignancies within families. Schildkraut JM; Thompson WD Genet Epidemiol; 1988; 5(5):355-67. PubMed ID: 3215509 [TBL] [Abstract][Full Text] [Related]
14. Cancer genetics in primary care. Culler D; Grimes SJ; Acheson LS; Wiesner GL Prim Care; 2004 Sep; 31(3):649-83, xi. PubMed ID: 15331253 [TBL] [Abstract][Full Text] [Related]
15. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations. Khabele D; Runowicz CD Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190 [TBL] [Abstract][Full Text] [Related]
16. Clinical implications of genetic testing for inherited breast and ovarian cancer risk. Calzone KA Nurs Spectr (Wash D C); 1998 Nov; 8(23):12-4. PubMed ID: 10542772 [No Abstract] [Full Text] [Related]
17. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
18. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
19. The pros and cons of genetic testing for breast and ovarian cancer risk. Frank TS; Braverman AM Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912 [TBL] [Abstract][Full Text] [Related]
20. [Tumor risk consultation for predisposed women from high risk cancer families]. Beckmann MW; Niederacher D; Bodden-Heidrich R; Goecke TO; Kuschel B; Achnoula M; Aba F; Schnürch HG; Bender HG Praxis (Bern 1994); 1998 Apr; 87(15):511-5. PubMed ID: 9608246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]